Advice
in the absence of a submission from the holder of the marketing authorisation
canakinumab (Ilaris ®) is not recommended for use within NHS Scotland.
Indication under review: Treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:
- tumour necrosis factor receptor associated periodic syndrome
- hyperimmunoglobulin D syndrome / mevalonate kinase deficiency
- Familial Mediterranean Fever
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice122KB (PDF)
Medicine details
- Medicine name:
- canakinumab (Ilaris)
- SMC ID:
- 1268/17
- Indication:
- treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older: •tumour necrosis factor receptor associated periodic syndrome •hyperimmunoglobulin D syndrome / mevalonate kinase deficiency •Familial Mediterranean Fever
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 07 August 2017